Novartis Ag (NVS) Revenue Growth (3y) (2017 - 2024)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Revenue Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
41.69% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
4.82% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
7.06% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
3.98% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
12.18% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
3.09% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-13.60% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
0.44% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
-20.70% |
| Dec 31, 2023 |
351.24% |
| Jun 30, 2023 |
4.35% |
| Mar 31, 2023 |
10.67% |
| Jun 30, 2022 |
-7.41% |
| Mar 31, 2022 |
3.03% |
| Dec 31, 2021 |
469.13% |
| Sep 30, 2021 |
-3.94% |
| Jun 30, 2021 |
-3.47% |
| Mar 31, 2021 |
9.85% |
| Dec 31, 2020 |
6.21% |
| Sep 30, 2020 |
7.42% |
| Jun 30, 2020 |
394.88% |
| Jun 30, 2019 |
483.36% |
| Mar 31, 2019 |
10,653.14% |
| Dec 31, 2018 |
51.94% |
| Sep 30, 2018 |
1,206,946.66% |
| Mar 31, 2018 |
11,122.29% |
| Dec 31, 2017 |
13,141.71% |
| Sep 30, 2017 |
12,633.25% |
